search
Back to results

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (TITANIA)

Primary Purpose

Chronic Obstructive Pulmonary Disease (COPD)

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Tozorakimab
Tozorakimab
Placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease (COPD) focused on measuring Chronic Obstructive Pulmonary Disease, COPD, tozorakimab, exacerbations, ICS, LABA/LAMA

Eligibility Criteria

40 Years - 130 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Participant must be ≥ 40 years of age and capable of giving signed informed consent.
  2. Documented diagnosis of COPD for at least one year prior to enrolment.
  3. Post BD FEV1/FVC < 0.70 and post-BD FEV1 >20% of predicted normal value.
  4. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.
  5. Documented optimized inhaled dual or triple therapy at a stable dose for at least 3 months prior to enrolment.
  6. Smoking history of ≥ 10 pack-years.
  7. CAT total score ≥10, with each of the phlegm (sputum) and cough items with a score ≥ 2

Exclusion Criteria:

  1. Clinically important pulmonary disease other than COPD.
  2. Radiological findings suggestive of a respiratory disease other than COPD that is contributing to the participant's respiratory symptoms.
  3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
  4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.
  5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization.
  6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.
  7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.
  8. Significant COVID-19 illness within the 6 months prior to enrolment.
  9. Unstable cardiovascular disorder.
  10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.
  11. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2.
  12. History of positive test or treatment for hepatitis B or hepatitis C (except for cured hepatitis C).
  13. Evidence of active liver disease, including jaundice during screening.
  14. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.
  15. Participants who have evidence of active TB.
  16. Participants that have previously received tozorakimab.
  17. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
  18. Active vaping of any products within the 6 months prior to randomization and during the study.

Sites / Locations

  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research SiteRecruiting
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Tozorakimab Dose 1

Tozorakimab Dose 2

Placebo

Arm Description

Dosing subcutaneously tozorakimab Dose 1 and placebo

Dosing subcutaneously tozorakimab Dose 2

Dosing subcutaneously with equivalent volume to tozorakimab

Outcomes

Primary Outcome Measures

Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.
The primary endpoint will be assessed first in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy [triple therapy, or dual therapy if triple is not considered appropriate]) and then assessed in the overall population of participants.

Secondary Outcome Measures

Annualized rate of moderate to severe COPD exacerbations in former or current smokers.
The annualized rate will be assessed in the overall population of participants including current and former smokers with symptomatic COPD and history of exacerbations, on optimised treatment with maintenance inhaled therapy.
Time to first moderate to severe COPD exacerbation in former smokers.
To explore the extent to which treatment with each dose of tozorakimab delays the time to first exacerbation compared with placebo in former smokers.
Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in former smokers.
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers.
Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in the overall population of current and former smokers.
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in the overall population of current and former smokers.
Percentage of responders achieving MCID in E-RS:COPD total score in former smokers
Responder analyses for E-RS:COPD total score at Week 52 based upon a ≥ 2 point improvement (decrease) from baseline in former smokers.
Percentage of responders achieving MCID in E-RS:COPD total score in the overall population of current and former smokers.
Responder analyses for E-RS:COPD total score at Week 52 based upon a ≥ 2 point improvement (decrease) from baseline in the overall population of current and former smokers.
Mean change from baseline in E-RS:COPD total score in former smokers.
Difference in mean change in E-RS:COPD total score from baseline in former smokers.
Mean change from baseline in E-RS:COPD total score in the overall population of current and former smokers.
Difference in mean change in E-RS:COPD total score from baseline in the overall population of current and former smokers.
Percentage of responders achieving MCID in SGRQ total score in former smokers.
Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline in former smokers.
Percentage of responders achieving MCID in SGRQ total score in the overall population of current and former smokers.
Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline in the overall population of current and former smokers.
Mean change from baseline in SGRQ total score from in former smokers.
Difference in mean change from baseline in SGRQ total score in former smokers.
Mean change from baseline in SGRQ total score from in the overall population of current and former smokers.
Difference in mean change from baseline in SGRQ total score in the overall population of current and former smokers.
Time to first severe COPD exacerbation in former smokers.
To evaluate hazard ratio of first severe COPD exacerbation in former smokers.
Annualized rate of severe COPD exacerbations in former smokers.
The rate ratio of severe COPD exacerbations will be assessed in former smokers.
Change from baseline in CAT total score.
Analyses of change from baseline in CAT total score in former smokers.
Percentage of participants with a decrease in CAT total score in former smokers.
Proportion of participants achieving MCID in CAT total score, a decrease in CAT total score of ≥ 2 points from baseline in former smokers.
Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.
Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.
Annualized rate of healthcare resource utilization in former smokers.
Annualized rate of healthcare resource utilization in former smokers.
The change from baseline in mean number of puffs per day in rescue use in former smokers.
Difference in mean number of puffs per day from baseline.
Trough serum concentrations of tozorakimab.
Pharmacokinetics: concentrations of tozorakimab in trough serum.
Presence of anti-drug antibodies.
Immunogenicity: presence of tozorakimab anti-drug antibodies in blood serum.

Full Information

First Posted
December 2, 2021
Last Updated
October 12, 2023
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT05158387
Brief Title
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Acronym
TITANIA
Official Title
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (TITANIA)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 7, 2022 (Actual)
Primary Completion Date
June 5, 2025 (Anticipated)
Study Completion Date
August 28, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease (COPD)
Keywords
Chronic Obstructive Pulmonary Disease, COPD, tozorakimab, exacerbations, ICS, LABA/LAMA

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
unblinded administrator/pharmacist
Allocation
Randomized
Enrollment
1060 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tozorakimab Dose 1
Arm Type
Experimental
Arm Description
Dosing subcutaneously tozorakimab Dose 1 and placebo
Arm Title
Tozorakimab Dose 2
Arm Type
Experimental
Arm Description
Dosing subcutaneously tozorakimab Dose 2
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Dosing subcutaneously with equivalent volume to tozorakimab
Intervention Type
Drug
Intervention Name(s)
Tozorakimab
Intervention Description
Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
Intervention Type
Drug
Intervention Name(s)
Tozorakimab
Intervention Description
Administered subcutaneously tozorakimab Dose 2 through Week 52.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
Primary Outcome Measure Information:
Title
Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.
Description
The primary endpoint will be assessed first in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy [triple therapy, or dual therapy if triple is not considered appropriate]) and then assessed in the overall population of participants.
Time Frame
over 52 weeks
Secondary Outcome Measure Information:
Title
Annualized rate of moderate to severe COPD exacerbations in former or current smokers.
Description
The annualized rate will be assessed in the overall population of participants including current and former smokers with symptomatic COPD and history of exacerbations, on optimised treatment with maintenance inhaled therapy.
Time Frame
over 52 weeks
Title
Time to first moderate to severe COPD exacerbation in former smokers.
Description
To explore the extent to which treatment with each dose of tozorakimab delays the time to first exacerbation compared with placebo in former smokers.
Time Frame
over 52 weeks
Title
Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in former smokers.
Description
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers.
Time Frame
Week 52, or over 52 weeks
Title
Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in the overall population of current and former smokers.
Description
Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in the overall population of current and former smokers.
Time Frame
Week 52, or over 52 weeks
Title
Percentage of responders achieving MCID in E-RS:COPD total score in former smokers
Description
Responder analyses for E-RS:COPD total score at Week 52 based upon a ≥ 2 point improvement (decrease) from baseline in former smokers.
Time Frame
Week 52
Title
Percentage of responders achieving MCID in E-RS:COPD total score in the overall population of current and former smokers.
Description
Responder analyses for E-RS:COPD total score at Week 52 based upon a ≥ 2 point improvement (decrease) from baseline in the overall population of current and former smokers.
Time Frame
Week 52
Title
Mean change from baseline in E-RS:COPD total score in former smokers.
Description
Difference in mean change in E-RS:COPD total score from baseline in former smokers.
Time Frame
over 52 weeks
Title
Mean change from baseline in E-RS:COPD total score in the overall population of current and former smokers.
Description
Difference in mean change in E-RS:COPD total score from baseline in the overall population of current and former smokers.
Time Frame
over 52 weeks
Title
Percentage of responders achieving MCID in SGRQ total score in former smokers.
Description
Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline in former smokers.
Time Frame
Week 52
Title
Percentage of responders achieving MCID in SGRQ total score in the overall population of current and former smokers.
Description
Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline in the overall population of current and former smokers.
Time Frame
Week 52
Title
Mean change from baseline in SGRQ total score from in former smokers.
Description
Difference in mean change from baseline in SGRQ total score in former smokers.
Time Frame
over 52 weeks
Title
Mean change from baseline in SGRQ total score from in the overall population of current and former smokers.
Description
Difference in mean change from baseline in SGRQ total score in the overall population of current and former smokers.
Time Frame
over 52 weeks
Title
Time to first severe COPD exacerbation in former smokers.
Description
To evaluate hazard ratio of first severe COPD exacerbation in former smokers.
Time Frame
over 52 weeks
Title
Annualized rate of severe COPD exacerbations in former smokers.
Description
The rate ratio of severe COPD exacerbations will be assessed in former smokers.
Time Frame
over 52 weeks
Title
Change from baseline in CAT total score.
Description
Analyses of change from baseline in CAT total score in former smokers.
Time Frame
Week 52
Title
Percentage of participants with a decrease in CAT total score in former smokers.
Description
Proportion of participants achieving MCID in CAT total score, a decrease in CAT total score of ≥ 2 points from baseline in former smokers.
Time Frame
Week 52
Title
Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.
Description
Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.
Time Frame
over 52 weeks
Title
Annualized rate of healthcare resource utilization in former smokers.
Description
Annualized rate of healthcare resource utilization in former smokers.
Time Frame
over 52 weeks
Title
The change from baseline in mean number of puffs per day in rescue use in former smokers.
Description
Difference in mean number of puffs per day from baseline.
Time Frame
over 52 weeks
Title
Trough serum concentrations of tozorakimab.
Description
Pharmacokinetics: concentrations of tozorakimab in trough serum.
Time Frame
over 52 weeks
Title
Presence of anti-drug antibodies.
Description
Immunogenicity: presence of tozorakimab anti-drug antibodies in blood serum.
Time Frame
over 60 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
130 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participant must be ≥ 40 years of age and capable of giving signed informed consent. Documented diagnosis of COPD for at least one year prior to enrolment. Post BD FEV1/FVC < 0.70 and post-BD FEV1 >20% of predicted normal value. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment. Documented optimized inhaled dual or triple therapy at a stable dose for at least 3 months prior to enrolment. Smoking history of ≥ 10 pack-years. CAT total score ≥10, with each of the phlegm (sputum) and cough items with a score ≥ 2 Exclusion Criteria: Clinically important pulmonary disease other than COPD. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection. Significant COVID-19 illness within the 6 months prior to enrolment. Unstable cardiovascular disorder. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2. History of positive test or treatment for hepatitis B or hepatitis C (except for cured hepatitis C) Evidence of active liver disease, including jaundice during screening. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms. Participants who have evidence of active TB. Participants that have previously received tozorakimab. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study. Active vaping of any products or using smoked marijuana within the 6 months prior to randomization and during the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
AstraZeneca Clinical Study Information Center
Phone
1-877-240-9479
Email
information.center@astrazeneca.com
Facility Information:
Facility Name
Research Site
City
Sheffield
State/Province
Alabama
ZIP/Postal Code
35660
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Lincoln
State/Province
California
ZIP/Postal Code
95648
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Northridge
State/Province
California
ZIP/Postal Code
91324
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
San Diego
State/Province
California
ZIP/Postal Code
92120
Country
United States
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80909
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Newark
State/Province
Delaware
ZIP/Postal Code
19713
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bay Pines
State/Province
Florida
ZIP/Postal Code
33744
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Cape Coral
State/Province
Florida
ZIP/Postal Code
33990
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Pensacola
State/Province
Florida
ZIP/Postal Code
32503
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Macon
State/Province
Georgia
ZIP/Postal Code
31201
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Greenwood
State/Province
Indiana
ZIP/Postal Code
46143
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bowling Green
State/Province
Kentucky
ZIP/Postal Code
42101
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
White Marsh
State/Province
Maryland
ZIP/Postal Code
21162
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
North Dartmouth
State/Province
Massachusetts
ZIP/Postal Code
02747
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Farmington Hills
State/Province
Michigan
ZIP/Postal Code
48336
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49546
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hannibal
State/Province
Missouri
ZIP/Postal Code
63401
Country
United States
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Bellevue
State/Province
Nebraska
ZIP/Postal Code
68123
Country
United States
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Bronx
State/Province
New York
ZIP/Postal Code
10459
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Buffalo
State/Province
New York
ZIP/Postal Code
14203
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43617
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73112
Country
United States
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74133
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rock Hill
State/Province
South Carolina
ZIP/Postal Code
29732
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Amarillo
State/Province
Texas
ZIP/Postal Code
79106
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Boerne
State/Province
Texas
ZIP/Postal Code
78006
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
McKinney
State/Province
Texas
ZIP/Postal Code
75069
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Webster
State/Province
Texas
ZIP/Postal Code
77598
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
West Valley City
State/Province
Utah
ZIP/Postal Code
84120
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Williamsburg
State/Province
Virginia
ZIP/Postal Code
23188
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Cudahy
State/Province
Wisconsin
ZIP/Postal Code
53110
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Site
City
Adelaide
ZIP/Postal Code
5000
Country
Australia
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Campbelltown
ZIP/Postal Code
2560
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Frankstown
ZIP/Postal Code
3199
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Macquarie University
ZIP/Postal Code
2109
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Melbourne
ZIP/Postal Code
3000
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nedlands
ZIP/Postal Code
6009
Country
Australia
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Southport
ZIP/Postal Code
4215
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Spearwood
ZIP/Postal Code
6163
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Wollongong
ZIP/Postal Code
2500
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Woodville South
ZIP/Postal Code
5011
Country
Australia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Blumenau
ZIP/Postal Code
89030-101
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Botucatu
ZIP/Postal Code
18618-686
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Brasilia
ZIP/Postal Code
71681-603
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Curitiba
ZIP/Postal Code
80440-220
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90035074
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
9061-000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
91010-006
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rio de Janeiro
ZIP/Postal Code
22061-080
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sao Bernardo do Campo
ZIP/Postal Code
09750-420
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sao Paulo
ZIP/Postal Code
01323-903
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Sao Paulo
ZIP/Postal Code
05403-000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
São Paulo
ZIP/Postal Code
01409-001
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Research Site
City
Curico
ZIP/Postal Code
3341643
Country
Chile
Individual Site Status
Recruiting
Facility Name
Research Site
City
Santiago
ZIP/Postal Code
7500010
Country
Chile
Individual Site Status
Recruiting
Facility Name
Research Site
City
Santiago
ZIP/Postal Code
7500657
Country
Chile
Individual Site Status
Recruiting
Facility Name
Research Site
City
Santiago
ZIP/Postal Code
7500698
Country
Chile
Individual Site Status
Recruiting
Facility Name
Research Site
City
Santiago
ZIP/Postal Code
8150000
Country
Chile
Individual Site Status
Recruiting
Facility Name
Research Site
City
Santiago
ZIP/Postal Code
8241479
Country
Chile
Individual Site Status
Recruiting
Facility Name
Research Site
City
Talca
ZIP/Postal Code
3465584
Country
Chile
Individual Site Status
Recruiting
Facility Name
Research Site
City
Anhui
ZIP/Postal Code
230061
Country
China
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Baotou
ZIP/Postal Code
014010
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Beijing
ZIP/Postal Code
100034
Country
China
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Beijing
ZIP/Postal Code
100144
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Beijing
ZIP/Postal Code
101200
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Changchun
ZIP/Postal Code
130021
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Changde
ZIP/Postal Code
415003
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Changsha
ZIP/Postal Code
410015
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chengdu
ZIP/Postal Code
610000
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chengdu
ZIP/Postal Code
610031
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chengdu
ZIP/Postal Code
610083
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chongqing
ZIP/Postal Code
400037
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chongqing
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Guangzhou
ZIP/Postal Code
510120
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Guangzhou
ZIP/Postal Code
510180
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Guangzhou
ZIP/Postal Code
510630
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Haikou
ZIP/Postal Code
570311
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hangzhou
ZIP/Postal Code
310006
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hefei
ZIP/Postal Code
230001
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Hohhot
ZIP/Postal Code
010017
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kunming
ZIP/Postal Code
650032
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Linhai
ZIP/Postal Code
317000
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nanchang
ZIP/Postal Code
330006
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nanchang
ZIP/Postal Code
330006
Country
China
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Nanjing
ZIP/Postal Code
210000
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nanjing
ZIP/Postal Code
210006
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ningbo
ZIP/Postal Code
315010
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shanghai
ZIP/Postal Code
200002
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shanghai
ZIP/Postal Code
200032
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shanghai
ZIP/Postal Code
200433
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shanghai
ZIP/Postal Code
201199
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shengyang
ZIP/Postal Code
110004
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shenyang
ZIP/Postal Code
110016
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shenzhen
ZIP/Postal Code
518020
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shenzhen
ZIP/Postal Code
518053
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shijiazhuang
ZIP/Postal Code
50051
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Suzhou
ZIP/Postal Code
215002
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Suzhou
ZIP/Postal Code
215004
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Taiyuan
ZIP/Postal Code
030001
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Tianjin
ZIP/Postal Code
300052
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Urumqi
ZIP/Postal Code
830054
Country
China
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Wuhan
ZIP/Postal Code
430022
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Wuxi
ZIP/Postal Code
214023
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Xiamen
ZIP/Postal Code
361004
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Xuzhou
ZIP/Postal Code
221000
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Xuzhou
ZIP/Postal Code
221009
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Yangzhou
ZIP/Postal Code
225001
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Yinchuan
ZIP/Postal Code
750001
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Yinchuan
ZIP/Postal Code
750004
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Zhanjiang
ZIP/Postal Code
524004
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Zunyi
ZIP/Postal Code
563100
Country
China
Individual Site Status
Recruiting
Facility Name
Research Site
City
Barranquilla
ZIP/Postal Code
80007
Country
Colombia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bogotá
ZIP/Postal Code
111211
Country
Colombia
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Ibague
ZIP/Postal Code
730006
Country
Colombia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Medellin
ZIP/Postal Code
050034
Country
Colombia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rionegro
ZIP/Postal Code
54040
Country
Colombia
Individual Site Status
Recruiting
Facility Name
Research Site
City
Zipaquira
ZIP/Postal Code
200251
Country
Colombia
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Brest Cedex 2
ZIP/Postal Code
29609
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Dijon Cedex
ZIP/Postal Code
21079
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Grenoble cedex 9
ZIP/Postal Code
38043
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Limoges
ZIP/Postal Code
87042
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Lyon Cedex
ZIP/Postal Code
69317
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Marseille
ZIP/Postal Code
13915
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Montivilliers
ZIP/Postal Code
76290
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Montpellier
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nantes
ZIP/Postal Code
44093
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Pessac
ZIP/Postal Code
33604
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Suresnes
ZIP/Postal Code
92150
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bamberg
ZIP/Postal Code
96049
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
10717
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
12157
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Darmstadt
ZIP/Postal Code
64283
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Frankfurt
ZIP/Postal Code
60596
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Großhansdorf
ZIP/Postal Code
22927
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Halle
ZIP/Postal Code
6108
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Köln
ZIP/Postal Code
51069
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Marburg
ZIP/Postal Code
35037
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
München-Pasing
ZIP/Postal Code
81241
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
München
ZIP/Postal Code
80336
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Peine
ZIP/Postal Code
31224
Country
Germany
Individual Site Status
Recruiting
Facility Name
Research Site
City
Alexandroupolis
ZIP/Postal Code
68100
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Athens
ZIP/Postal Code
11527
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Exohi Thessaloniki
ZIP/Postal Code
57010
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ioannina
ZIP/Postal Code
45500
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Patras
ZIP/Postal Code
26500
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Thessaloniki
ZIP/Postal Code
57010
Country
Greece
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ashkelon
ZIP/Postal Code
78278
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Beer Sheva
ZIP/Postal Code
8410101
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Jerusalem
ZIP/Postal Code
9372212
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kfar-Saba
ZIP/Postal Code
4428164
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Rehovot
ZIP/Postal Code
76100
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Tel Aviv
ZIP/Postal Code
6423906
Country
Israel
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bari
ZIP/Postal Code
70124
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Macerata
ZIP/Postal Code
62100
Country
Italy
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Massa
ZIP/Postal Code
54100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Messina
ZIP/Postal Code
98124
Country
Italy
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Milano
ZIP/Postal Code
20142
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Milano
ZIP/Postal Code
20157
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Roma
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Salerno
ZIP/Postal Code
84131
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
San Donà di Piave
ZIP/Postal Code
30027
Country
Italy
Individual Site Status
Terminated
Facility Name
Research Site
City
Sassari
ZIP/Postal Code
07100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Statte
ZIP/Postal Code
74010
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Telese Terme
ZIP/Postal Code
82037
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Tradate
ZIP/Postal Code
21049
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Vercelli
ZIP/Postal Code
13100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Verona
ZIP/Postal Code
37134
Country
Italy
Individual Site Status
Recruiting
Facility Name
Research Site
City
Lima
ZIP/Postal Code
15036
Country
Peru
Individual Site Status
Recruiting
Facility Name
Research Site
City
Lima
ZIP/Postal Code
15046
Country
Peru
Individual Site Status
Recruiting
Facility Name
Research Site
City
Lima
ZIP/Postal Code
15088
Country
Peru
Individual Site Status
Recruiting
Facility Name
Research Site
City
Lima
ZIP/Postal Code
L18
Country
Peru
Individual Site Status
Recruiting
Facility Name
Research Site
City
Lima
ZIP/Postal Code
LIMA 21
Country
Peru
Individual Site Status
Recruiting
Facility Name
Research Site
City
Lima
ZIP/Postal Code
LIMA 31
Country
Peru
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Piura
ZIP/Postal Code
20001
Country
Peru
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Baguio
ZIP/Postal Code
2600
Country
Philippines
Individual Site Status
Recruiting
Facility Name
Research Site
City
Cebu City
ZIP/Postal Code
6000
Country
Philippines
Individual Site Status
Recruiting
Facility Name
Research Site
City
Iloilo City
ZIP/Postal Code
5000
Country
Philippines
Individual Site Status
Recruiting
Facility Name
Research Site
City
Manila
ZIP/Postal Code
1000
Country
Philippines
Individual Site Status
Recruiting
Facility Name
Research Site
City
Białystok
ZIP/Postal Code
15-044
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Białystok
ZIP/Postal Code
15-430
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Białystok
ZIP/Postal Code
15-704
Country
Poland
Individual Site Status
Suspended
Facility Name
Research Site
City
Bychawa
ZIP/Postal Code
23100
Country
Poland
Individual Site Status
Suspended
Facility Name
Research Site
City
Bydgoszcz
ZIP/Postal Code
85-796
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Gdańsk
ZIP/Postal Code
80-214
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Grudziądz
ZIP/Postal Code
86-300
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Katowice
ZIP/Postal Code
40-648
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Krakow
ZIP/Postal Code
30-033
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kraków
ZIP/Postal Code
31-559
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Lublin
ZIP/Postal Code
20-412
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nowa Sól
ZIP/Postal Code
67-100
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Ostrowiec Świętokrzyski
ZIP/Postal Code
27-400
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ostróda
ZIP/Postal Code
14-100
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Poznań
ZIP/Postal Code
60-693
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Poznań
ZIP/Postal Code
61-578
Country
Poland
Individual Site Status
Completed
Facility Name
Research Site
City
Poznań
ZIP/Postal Code
61-731
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Rzeszów
ZIP/Postal Code
35-205
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Skierniewice
ZIP/Postal Code
96-100
Country
Poland
Individual Site Status
Completed
Facility Name
Research Site
City
Sosnowiec
ZIP/Postal Code
41-208
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Warszawa
ZIP/Postal Code
04-141
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Wołomin
ZIP/Postal Code
05-200
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Wroclaw
ZIP/Postal Code
54-239
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Wrocław
ZIP/Postal Code
53-301
Country
Poland
Individual Site Status
Recruiting
Facility Name
Research Site
City
Caguas
ZIP/Postal Code
00726
Country
Puerto Rico
Individual Site Status
Recruiting
Facility Name
Research Site
City
Ponce
ZIP/Postal Code
00717
Country
Puerto Rico
Individual Site Status
Recruiting
Facility Name
Research Site
City
Brasov
ZIP/Postal Code
500283
Country
Romania
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bucharest
ZIP/Postal Code
50159
Country
Romania
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Bucuresti
ZIP/Postal Code
014142
Country
Romania
Individual Site Status
Not yet recruiting
Facility Name
Research Site
City
Cluj-Napoca
ZIP/Postal Code
400371
Country
Romania
Individual Site Status
Recruiting
Facility Name
Research Site
City
Constanta
ZIP/Postal Code
900002
Country
Romania
Individual Site Status
Recruiting
Facility Name
Research Site
City
Iasi
ZIP/Postal Code
700304
Country
Romania
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Timisoara
ZIP/Postal Code
300002
Country
Romania
Individual Site Status
Recruiting
Facility Name
Research Site
City
Chelyabinsk
ZIP/Postal Code
454106
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Izhevsk
ZIP/Postal Code
426061
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Moscow
ZIP/Postal Code
105077
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Moscow
ZIP/Postal Code
107150
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Novosibirsk
ZIP/Postal Code
630008
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Penza
ZIP/Postal Code
440067
Country
Russian Federation
Individual Site Status
Terminated
Facility Name
Research Site
City
Perm
ZIP/Postal Code
614000
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Saint Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Saratov
ZIP/Postal Code
410012
Country
Russian Federation
Individual Site Status
Completed
Facility Name
Research Site
City
Tomsk
ZIP/Postal Code
634034
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Ulyanovsk
ZIP/Postal Code
432009
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Hsinchu
ZIP/Postal Code
300
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kaohsiung
ZIP/Postal Code
807
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Kaohsiung
ZIP/Postal Code
82445
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Taichung
ZIP/Postal Code
40443
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Taichung
ZIP/Postal Code
40705
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Taoyuan
ZIP/Postal Code
333
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Yunlin
ZIP/Postal Code
640
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bang Kra So
ZIP/Postal Code
11000
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Individual Site Status
Active, not recruiting
Facility Name
Research Site
City
Hat Yai
ZIP/Postal Code
90110
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Khon Kaen
ZIP/Postal Code
40000
Country
Thailand
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Khon Kaen
ZIP/Postal Code
40002
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Muang,
ZIP/Postal Code
55000
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Muang
ZIP/Postal Code
22000
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Mueang
ZIP/Postal Code
20000
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Nakhon Ratchasima
ZIP/Postal Code
30000
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Research Site
City
Blackpool
ZIP/Postal Code
FY4 3AD
Country
United Kingdom
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Bradford
ZIP/Postal Code
BD9 6RJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Corby
ZIP/Postal Code
NN17 2UR
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Corby
ZIP/Postal Code
NN18 9EZ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Enfield
ZIP/Postal Code
EN3 4GS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Glasgow
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Hampshire
ZIP/Postal Code
SO16 6YD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
High Wycombe
ZIP/Postal Code
HP11 2QW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
London
ZIP/Postal Code
NW3 2QG
Country
United Kingdom
Individual Site Status
Withdrawn
Facility Name
Research Site
City
Northwood
ZIP/Postal Code
HA6 2RN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Preston
ZIP/Postal Code
PR2 9QB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Shipley
ZIP/Postal Code
BD18 3SA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Research Site
City
Wokingham
ZIP/Postal Code
RG40 1XS
Country
United Kingdom
Individual Site Status
Withdrawn

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

We'll reach out to this number within 24 hrs